<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id>
<journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group>
<journal-title>PLoS Computational Biology</journal-title></journal-title-group>
<issn pub-type="ppub">1553-734X</issn>
<issn pub-type="epub">1553-7358</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PCOMPBIOL-D-13-01794</article-id>
<article-id pub-id-type="doi">10.1371/journal.pcbi.1003730</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and life sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune response</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Infectious diseases</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Applied mathematics</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Antibody Responses during Hepatitis B Viral Infection</article-title>
<alt-title alt-title-type="running-head">Antibody Responses during HBV Infection</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ciupe</surname><given-names>Stanca M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ribeiro</surname><given-names>Ruy M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>Alan S.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Department of Mathematics, Virginia Tech, Blacksburg, Virginia, United States of America</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Regoes</surname><given-names>Roland R.</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>ETH Zurich, Switzerland</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">stanca@math.vt.edu</email></corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: SMC RMR ASP. Performed the experiments: SMC. Analyzed the data: SMC. Contributed reagents/materials/analysis tools: SMC. Wrote the paper: SMC RMR ASP.</p></fn>
</author-notes>
<pub-date pub-type="collection"><month>7</month><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>31</day><month>7</month><year>2014</year></pub-date>
<volume>10</volume>
<issue>7</issue>
<elocation-id>e1003730</elocation-id>
<history>
<date date-type="received"><day>11</day><month>10</month><year>2013</year></date>
<date date-type="accepted"><day>16</day><month>5</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<license xlink:type="simple"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</license-p></license></permissions>
<abstract>
<p>Hepatitis B is a DNA virus that infects liver cells and can cause both acute and chronic disease. It is believed that both viral and host factors are responsible for determining whether the infection is cleared or becomes chronic. Here we investigate the mechanism of protection by developing a mathematical model of the antibody response following hepatitis B virus (HBV) infection. We fitted the model to data from seven infected adults identified during acute infection and determined the ability of the virus to escape neutralization through overproduction of non-infectious subviral particles, which have HBs proteins on their surface, but do not contain nucleocapsid protein and viral nucleic acids. We showed that viral clearance can be achieved for high anti-HBV antibody levels, as in vaccinated individuals, when: (1) the rate of synthesis of hepatitis B subviral particles is slow; (2) the rate of synthesis of hepatitis B subviral particles is high but either anti-HBV antibody production is fast, the antibody affinity is high, or the levels of pre-existent HBV-specific antibody at the time of infection are high, as could be attained by vaccination. We further showed that viral clearance can be achieved for low equilibrium anti-HBV antibody levels, as in unvaccinated individuals, when a strong cellular immune response controls early infection.</p>
</abstract>
<abstract abstract-type="summary"><title>Author Summary</title>
<p>Hepatitis B vaccine induces life-long protection in vaccinated individuals. In the absence of vaccination, however, hepatitis B virus can cause both self-limiting and chronic disease. We investigate whether antibodies against hepatitis B play a role in virus clearance. We developed a mathematical model that describes the production of antibodies to both infectious virus and non-infectious subviral particles (with hepatitis B surface proteins, but no nucleic acids) and compared the model to patient data. We predict that high levels of antibodies, either pre-existing, as in vaccinated individuals, or through fast expansion, can control the infection and lead to viral clearance. However, when the antibody levels are more similar to those observed in a clinical context, cellular immune responses are needed to control the virus and antibodies act only in late stages to aid in viral clearance.</p>
</abstract>
<funding-group><funding-statement>SMC acknowledges support from NSF grant DMS-1214582. Portions of this work were performed under the auspices of the U.S. Department of Energy under contract DE-AC52-06NA25396 and supported by NIH grants P20-GM103452, AI028433 and OD011095. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="16"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Infection with hepatitis B virus (HBV) results in acute hepatitis followed by recovery in 85%–95% of human adults <xref ref-type="bibr" rid="pcbi.1003730-Hollinger1">[1]</xref>. Recovery occurs when the organism mounts adequate immune responses against the virus. Such responses include production of protective, neutralizing antibodies against HBV surface antigen (HBsAg) <xref ref-type="bibr" rid="pcbi.1003730-Rehermann1">[2]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Waters1">[3]</xref>, activation of strong and diversified CD4 and CD8 T-cells <xref ref-type="bibr" rid="pcbi.1003730-Ferrari1">[4]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Rehermann1">[2]</xref>, expression of antiviral cytokines in the liver, such as gamma interferon and tumor necrosis factor alpha <xref ref-type="bibr" rid="pcbi.1003730-Guidotti1">[5]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-McClary1">[6]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Wieland1">[7]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Wieland2">[8]</xref>, and generation of cells that are protected from reinfection <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Guo1">[10]</xref>. In contrast, progression to chronic HBV infection occurs predominantly in immuno-compromised adults and in unvaccinated infants <xref ref-type="bibr" rid="pcbi.1003730-Chisari1">[11]</xref>. Such individuals exhibit weak and inefficient humoral and cellular immune responses, resulting in continual virus replication and HBV surface antigenemia <xref ref-type="bibr" rid="pcbi.1003730-Bertoletti1">[12]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ferrari1">[4]</xref>. Little is known about the relative contributions of different arms of the immune system, especially the roles of neutralizing antibodies in the onset and outcome of infection.</p>
<p>The antibody response to HBV infection is difficult to study experimentally. Free antibody to surface antigen is not detected until after the resolution of HBV infection <xref ref-type="bibr" rid="pcbi.1003730-Lai1">[13]</xref>. However, circulating immune complexes containing antibody and HBsAg are found in both acute and chronic HBV infections, suggesting that antibodies are produced much sooner than detected, and that they might play a role in the pathology of the disease <xref ref-type="bibr" rid="pcbi.1003730-AnhTuan1">[14]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Brown1">[15]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Glebe1">[16]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Rath1">[17]</xref>. HBsAg-specific antibodies have neutralizing properties and mediate protective immunity <xref ref-type="bibr" rid="pcbi.1003730-Glebe1">[16]</xref>.</p>
<p>Infection with hepatitis B virus results in the synthesis of a large number, probably of at least 1,000-fold, of “subviral particles” (SVPs) in relation to HBV particles <xref ref-type="bibr" rid="pcbi.1003730-Hollinger1">[1]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Prange1">[18]</xref>. SVPs, which are produced by HBV infected cells, are particles that have HBV proteins on their surface, but do not contain nucleocapsid protein and viral nucleic acids and hence are non-infectious <xref ref-type="bibr" rid="pcbi.1003730-Ganem1">[19]</xref>. They exist in two main forms: spheres 25 nm in diameter and filaments 22 nm in diameter with variable lengths <xref ref-type="bibr" rid="pcbi.1003730-Glebe2">[20]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ganem2">[21]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Gilbert1">[22]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Patient1">[23]</xref>. The reasons for their overproduction and their contribution to HBV pathogenesis is still under investigation <xref ref-type="bibr" rid="pcbi.1003730-Garcia1">[24]</xref>. SVPs may influence the way the host reacts to HBV infection. They may induce tolerance during perinatal infection, thus delaying the rise of neutralizing antibodies. Additionally, the excess of subviral particles can serve as a decoy by adsorbing neutralizing antibodies and therefore delay the clearance of infection.</p>
<p>In this paper, we aim to determine quantitative features of the antibody responses to virus and subviral particles following HBV infection. We build on basic chronic virus infection models <xref ref-type="bibr" rid="pcbi.1003730-Nowak1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Nowak2">[26]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Perelson1">[27]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Perelson2">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Stafford1">[29]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Lewin1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Tsiang1">[31]</xref> and determine the antibody characteristics that explain both the high peak and eventual viral clearance observed during acute hepatitis B infections <xref ref-type="bibr" rid="pcbi.1003730-Wieland2">[8]</xref>. We show that antibody responses can lead to viral clearance when the anti-HBV levels are high, as in vaccinated patients, and: (1) the rate of synthesis of hepatitis B subviral particles is slow; (2) the rate of synthesis of hepatitis B subviral particles is high but either anti-HBV antibody production is fast, the antibodies have high affinity, or the levels of pre-existent HBV-specific antibody at the time of infection are high. For lower anti-HBV antibody levels, as in unvaccinated patients, both cellular and humoral responses are needed in concert to clear acute HBV infection with the CD8 T cells controlling the initial burst of replication and the antibodies preventing virus rebound. The paper is structured as follows. In section Methods we develop the general model of antibody responses to viral and the subviral particles. In section Analytical results we analyze it analytically using asymptotic analysis techniques and in section Numerical results we present numerical results and compare these to data of primary HBV infection in humans, and present alternative models. We conclude with a discussion.</p>
</sec><sec id="s2" sec-type="methods">
<title>Methods</title>
<sec id="s2a">
<title>Models of virus infection in the absence of antibody responses</title>
<p>Standard mathematical models of viral infections consider dynamics and relations among uninfected target cells (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e001" xlink:type="simple"/></inline-formula>), infected cells (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e002" xlink:type="simple"/></inline-formula>), and virus (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e003" xlink:type="simple"/></inline-formula>) <xref ref-type="bibr" rid="pcbi.1003730-Nowak1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Nowak2">[26]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Perelson1">[27]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Perelson2">[28]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Stafford1">[29]</xref>. Briefly, these models assume that target cells <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e004" xlink:type="simple"/></inline-formula> become infected at a rate proportional to both the target cell concentration and the virus concentration, <italic>i.e.</italic>, at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e005" xlink:type="simple"/></inline-formula>. Infected cells are thus produced at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e006" xlink:type="simple"/></inline-formula> and die at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e007" xlink:type="simple"/></inline-formula> (that includes immune system mediated killing). Virus is produced by infected cells at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e008" xlink:type="simple"/></inline-formula> and is cleared at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e009" xlink:type="simple"/></inline-formula>. These models have been adapted to describe hepatitis B virus infection where the target population is liver cells (hepatocytes) <xref ref-type="bibr" rid="pcbi.1003730-Lewin1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Nowak1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Tsiang1">[31]</xref>. The model accounts for the liver's ability to regenerate following injury <xref ref-type="bibr" rid="pcbi.1003730-Lambotte1">[32]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Michalopoulos1">[33]</xref>. This regeneration, accomplished by several cycles of hepatocyte mitosis, is described by a logistic term with carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e010" xlink:type="simple"/></inline-formula> and maximal proliferation rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e011" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ciupe2">[34]</xref>. Moreover, infected hepatocytes can be cured <xref ref-type="bibr" rid="pcbi.1003730-Guo1">[10]</xref> and move back into the target population at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e012" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Lewin1">[30]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Tsiang1">[31]</xref>. The dynamics of the system are governed by the following equations<disp-formula id="pcbi.1003730.e013"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e013" xlink:type="simple"/><label>(1)</label></disp-formula>where for acute infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e014" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e015" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e016" xlink:type="simple"/></inline-formula>. An analysis of this system predicts two outcomes <xref ref-type="bibr" rid="pcbi.1003730-Bonhoeffer1">[35]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ribeiro1">[36]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Nowak3">[37]</xref>. The infection dies out when<disp-formula id="pcbi.1003730.e017"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e017" xlink:type="simple"/></disp-formula>and the infection takes off and leads to chronic hepatitis when<disp-formula id="pcbi.1003730.e018"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e018" xlink:type="simple"/></disp-formula></p>
<p>This simple system, which lacks any explicit immune response, does not explain transient infections, where the liver gets infected, <italic>i.e.</italic>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e019" xlink:type="simple"/></inline-formula>, but the infection is eventually cleared, presumably by the immune system. Clearance of HBV infection occurs in 90% of adults infected with HBV <xref ref-type="bibr" rid="pcbi.1003730-Hollinger1">[1]</xref>. While the role of the cellular immune responses has been studied both theoretically and experimentally <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ciupe2">[34]</xref>,<xref ref-type="bibr" rid="pcbi.1003730-Murray1">[38]</xref>,<xref ref-type="bibr" rid="pcbi.1003730-Sprengers1">[39]</xref>, less is known about the dynamics of the humoral immune response to HBV <xref ref-type="bibr" rid="pcbi.1003730-Yousfi1">[40]</xref>. In the following section we investigate antibody responses by modifying system (1) to account for humoral immunity following HBV infection.</p>
</sec><sec id="s2b">
<title>A model of HBV infection including an antibody response</title>
<p>To include the antibody response, we generalize the model given by Eq. (1) by considering seven populations, corresponding to target cells (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e020" xlink:type="simple"/></inline-formula>), which are mostly or exclusively uninfected hepatocytes, productively infected cells (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e021" xlink:type="simple"/></inline-formula>), free virus (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e022" xlink:type="simple"/></inline-formula>), free subviral particles (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e023" xlink:type="simple"/></inline-formula>), free antibody (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e024" xlink:type="simple"/></inline-formula>), virus-antibody complexes (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e025" xlink:type="simple"/></inline-formula>), and subviral particle-antibody complexes (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e026" xlink:type="simple"/></inline-formula>). Since hepatocytes are in contact with the blood we assume, as above, that their infection can be described by a well-mixed system. Further investigation is needed to know whether spatial effects are important in HBV infection. For hepatitis C virus (HCV) infection, in which a much smaller fraction of cells become infected, spatial clustering of infected cells has recently been observed <xref ref-type="bibr" rid="pcbi.1003730-Kandathil1">[41]</xref>.</p>
<p>As in Eq. (1), we assumed that target cells are maintained through homeostasis described by the logistic term with carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e027" xlink:type="simple"/></inline-formula> and maximum proliferation rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e028" xlink:type="simple"/></inline-formula>, and become infected at a rate proportional to both the target cell concentration and the virus concentration, <italic>i.e.</italic>, at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e029" xlink:type="simple"/></inline-formula>. Infected cells are thus produced at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e030" xlink:type="simple"/></inline-formula> and die at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e031" xlink:type="simple"/></inline-formula> (that includes immune system mediated killing). Upon infection, virus and subviral particles are produced at rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e032" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e033" xlink:type="simple"/></inline-formula>, and cleared at rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e034" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e035" xlink:type="simple"/></inline-formula>, respectively. We neglect the curing of infected cells by setting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e036" xlink:type="simple"/></inline-formula>. With this simplification the basic reproductive number becomes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e037" xlink:type="simple"/></inline-formula>.</p>
<p>Previous papers <xref ref-type="bibr" rid="pcbi.1003730-Dibrov1">[42]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Oprea1">[43]</xref> have presented detailed models of B lymphocyte proliferation and differentiation into plasmablast, antibody producing plasma cells and memory cells after they encounter antigen. For simplicity, we ignore the details of B-lymphocyte dynamics and differentiation into antibody producing cells and assume that free antibody (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e038" xlink:type="simple"/></inline-formula>), is produced at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e039" xlink:type="simple"/></inline-formula> proportional to the antigen load, <italic>i.e</italic>, the viral and subviral concentrations, and is degraded at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e040" xlink:type="simple"/></inline-formula>. Antibody is maintained after virus is cleared through antigen-independent homeostatic proliferation of memory B cells and long-lived plasma cells. In order to model this in a simple way, we add a logistic term to the antibody equation with maximum proliferation rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e041" xlink:type="simple"/></inline-formula> and carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e042" xlink:type="simple"/></inline-formula>. We show (in section 4.3) that a model that explicitly includes B cell dynamics has behavior similar to this simpler model with antibody alone.</p>
<p>Antigen elimination is facilitated by the formation of antigen-antibody complexes. We consider the reversible binding of free anti-HBsAg antibody (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e043" xlink:type="simple"/></inline-formula>), to both free virus (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e044" xlink:type="simple"/></inline-formula>), and subviral particles (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e045" xlink:type="simple"/></inline-formula>), described by the reaction scheme<disp-formula id="pcbi.1003730.e046"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e046" xlink:type="simple"/><label>(2)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e047" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e048" xlink:type="simple"/></inline-formula> are the complexes formed between antibody and the viral and subviral particles, respectively. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e049" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e050" xlink:type="simple"/></inline-formula> are binding rate constants, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e051" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e052" xlink:type="simple"/></inline-formula> are disassociation rate constants for antibody reacting to viral and subviral particles, respectively. We consider that complexes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e053" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e054" xlink:type="simple"/></inline-formula> are degraded at a constant rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e055" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e056" xlink:type="simple"/></inline-formula>. Antibodies can also bind infected cells budding virus. In this model we consider this to occur at a small rate and we neglect it.</p>
<p>Based on the scheme (2) and the assumptions above we construct the following equations of virus-host interaction<disp-formula id="pcbi.1003730.e057"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e057" xlink:type="simple"/><label>(3)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e058" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e059" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e060" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e061" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e062" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e063" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e064" xlink:type="simple"/></inline-formula>. The total concentration of viral DNA is described by<disp-formula id="pcbi.1003730.e065"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e065" xlink:type="simple"/><label>(4)</label></disp-formula>and the total concentration of anti-HBsAg antibody is given by<disp-formula id="pcbi.1003730.e066"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e066" xlink:type="simple"/><label>(5)</label></disp-formula></p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Analytical results</title>
<sec id="s3a1">
<title>Quasi-equilibrium of subviral particles</title>
<p>Not much is known about the differences in antibody response to viral and subviral particles. Therefore, for simplicity and to gain analytical insights into the model's behavior, we assume that the antibody association and disassociation rates and clearance rates are equal for the viral and subviral particles and virus-antibody and subviral particle-antibody complexes, <italic>i.e.</italic> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e067" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e068" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e069" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e070" xlink:type="simple"/></inline-formula>. In section 4, we relax these simplifying assumptions. From the equilibrium of the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e071" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e072" xlink:type="simple"/></inline-formula> equations, we obtain that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e073" xlink:type="simple"/></inline-formula>. Similarly, at equilibrium<disp-formula id="pcbi.1003730.e074"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e074" xlink:type="simple"/><label>(6)</label></disp-formula>from which it follows that, at equilibrium the concentration of subviral particles (free and bound) is proportional to the concentration of the virus (free and bound), <italic>i.e.</italic> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e075" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e076" xlink:type="simple"/></inline-formula>. Assuming quasi-steady state between the subviral particles and the free virus, we can incorporate these proportionalities into the system given by (3), reducing it to<disp-formula id="pcbi.1003730.e077"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e077" xlink:type="simple"/><label>(7)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e078" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e079" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e080" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e081" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e082" xlink:type="simple"/></inline-formula>. The <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e083" xlink:type="simple"/></inline-formula> terms are included to account for the antibody binding to SVPs. We will refer to system (7) as the antibody model.</p>
</sec><sec id="s3a2">
<title>Asymptotic analysis</title>
<p>We rewrite the terms on the right hand side of system (7) describing antibody dynamics in the absence of virus as follows:<disp-formula id="pcbi.1003730.e084"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e084" xlink:type="simple"/><label>(8)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e085" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e086" xlink:type="simple"/></inline-formula> and study the long term behavior of system (7).</p>
<p>We distinguish between different scenarios of hepatitis B infection outcome (failure, exposure without establishment of infection, cleared and chronic infections) based on the relative parameter values. The system has the following non-negative steady states</p>
<list list-type="alpha-lower"><list-item>
<p>Infection cleared with liver failure in the absence of immune response<disp-formula id="pcbi.1003730.e087"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e087" xlink:type="simple"/><label>(9)</label></disp-formula></p>
</list-item><list-item>
<p>Infection cleared with liver failure in the presence of immune response<disp-formula id="pcbi.1003730.e088"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e088" xlink:type="simple"/><label>(10)</label></disp-formula></p>
</list-item><list-item>
<p>No-infection steady state<disp-formula id="pcbi.1003730.e089"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e089" xlink:type="simple"/><label>(11)</label></disp-formula></p>
</list-item><list-item>
<p>Cleared infection steady state, in the presence of an immune response<disp-formula id="pcbi.1003730.e090"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e090" xlink:type="simple"/><label>(12)</label></disp-formula></p>
</list-item><list-item>
<p>Chronic infection steady states<disp-formula id="pcbi.1003730.e091"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e091" xlink:type="simple"/><label>(13)</label></disp-formula>with<disp-formula id="pcbi.1003730.e092"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e092" xlink:type="simple"/><label>(14)</label></disp-formula>where<disp-formula id="pcbi.1003730.e093"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e093" xlink:type="simple"/><label>(15)</label></disp-formula></p>
</list-item></list>
<p>When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e094" xlink:type="simple"/></inline-formula> we have that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e095" xlink:type="simple"/></inline-formula>. Therefore, since <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e096" xlink:type="simple"/></inline-formula>, by Decartes' rule of signs, the polynomial in Eq. (14) can have one or three positive roots. Since we require positivity for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e097" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e098" xlink:type="simple"/></inline-formula>, which is equivalent to<disp-formula id="pcbi.1003730.e099"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e099" xlink:type="simple"/><label>(16)</label></disp-formula>and to expression <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e100" xlink:type="simple"/></inline-formula>, which is satisfied when<disp-formula id="pcbi.1003730.e101"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e101" xlink:type="simple"/><label>(17)</label></disp-formula></p>
<p>We cannot give definite conditions for when three roots emerge.</p>
<p>For each of the steady state solutions, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e102" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e103" xlink:type="simple"/></inline-formula>, we can analyze the local stability by studying the Jacobian matrix<disp-formula id="pcbi.1003730.e104"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e104" xlink:type="simple"/><label>(18)</label></disp-formula></p>
<p><bold>Proposition 1.</bold> <italic>The liver failure steady states </italic><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e105" xlink:type="simple"/></inline-formula><italic> and </italic><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e106" xlink:type="simple"/></inline-formula><italic> are always unstable.</italic></p>
<p><bold>Proposition 2.</bold> <italic>The no-infection steady state </italic><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e107" xlink:type="simple"/></inline-formula><italic> is always unstable.</italic></p>
<p><bold>Proposition 3.</bold> <italic>The cleared infection steady state </italic><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e108" xlink:type="simple"/></inline-formula><italic> is locally asymptotically stable when</italic><disp-formula id="pcbi.1003730.e109"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e109" xlink:type="simple"/><label>(19)</label></disp-formula><italic>and unstable otherwise.</italic></p>
<p><italic>Proof.</italic> The characteristic equation is given by<disp-formula id="pcbi.1003730.e110"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e110" xlink:type="simple"/><label>(20)</label></disp-formula>where<disp-formula id="pcbi.1003730.e111"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e111" xlink:type="simple"/><label>(21)</label></disp-formula></p>
<p>By Routh-Hurwitz conditions <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e112" xlink:type="simple"/></inline-formula> is locally asymptotically stable when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e113" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e114" xlink:type="simple"/></inline-formula>, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e115" xlink:type="simple"/></inline-formula>. This happens when condition (19) holds. Conversely, when (19) fails <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e116" xlink:type="simple"/></inline-formula> is unstable.</p>
<p>Finding explicit parameter values for the existence of chronic steady states and studying their stability is possible, but tedious and will not be presented here.</p>
<p>If <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e117" xlink:type="simple"/></inline-formula> clearance cannot be attained. Instead either a locally asymptotically stable chronic steady state or a limit cycle emerges regardless of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e118" xlink:type="simple"/></inline-formula>, as we will illustrate numerically. If <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e119" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e120" xlink:type="simple"/></inline-formula> then, from (16) and (17), the chronic steady state <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e121" xlink:type="simple"/></inline-formula> does not exist. Numerical results show that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e122" xlink:type="simple"/></inline-formula>, which is locally asymptotically stable under these conditions for all <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e123" xlink:type="simple"/></inline-formula>, will attract all solutions. Finally, when the cleared infection steady state is locally asymptotically stable and the chronic steady state exists, <italic>i.e.</italic>, when<disp-formula id="pcbi.1003730.e124"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e124" xlink:type="simple"/><label>(22)</label></disp-formula>we observe bistability of the cleared infection and chronic steady states <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e125" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e126" xlink:type="simple"/></inline-formula>.</p>
<p>It is interesting to think of<disp-formula id="pcbi.1003730.e127"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e127" xlink:type="simple"/></disp-formula>as a new effective basic reproductive number giving the condition for chronic infection in the presence of antibodies. Indeed, when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e128" xlink:type="simple"/></inline-formula> the infection is sustained (as a chronic locally asymptotically stable steady state or a limit cycle). When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e129" xlink:type="simple"/></inline-formula>, however, bistability between clearance and chronic steady states occurs when (22) is satisfied.</p>
<p>In the next section we will investigate these types of behaviors numerically.</p>
</sec></sec><sec id="s3b">
<title>Numerical results</title>
<sec id="s3b1">
<title>Parameter values</title>
<p>After injury the liver can rapidly regenerate. We assume that during infection the maximum proliferation rate for uninfected hepatocytes is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e130" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Lodish1">[44]</xref>, corresponding to approximately a division every <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e131" xlink:type="simple"/></inline-formula> hours. The total number of hepatocytes in the liver, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e132" xlink:type="simple"/></inline-formula>, has been estimated at about <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e133" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Sherlock1">[45]</xref>, and assuming HBV can distribute throughout the 15 liters of extracellular fluid in the average 70 kg person, we normalize the liver cell population as done in previous models <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Dahari1">[46]</xref> so that we consider the cells responsible for producing virus in one ml. Hence, we take <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e134" xlink:type="simple"/></inline-formula> cells per ml. We use the estimates from earlier studies for the viral clearance rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e135" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Nowak1">[25]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Tsiang1">[31]</xref>. We consider the entire liver to be susceptible to infection, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e136" xlink:type="simple"/></inline-formula>, no initial infection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e137" xlink:type="simple"/></inline-formula> and an HBV inoculum of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e138" xlink:type="simple"/></inline-formula> virions per ml <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. Each virion contains one HBV DNA molecule and typically HBV DNA per ml is measured as a surrogate for virions per ml.</p>
<p>The serum immunoglobulin IgG concentration in healthy adult individuals ranges between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e139" xlink:type="simple"/></inline-formula>–<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e140" xlink:type="simple"/></inline-formula> mg/ml <xref ref-type="bibr" rid="pcbi.1003730-Dati1">[47]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-GonzalezQuintela1">[48]</xref>. We assume that at most <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e141" xlink:type="simple"/></inline-formula> of IgG levels are HBsAg-specific and thus set the antibody carrying capacity to 1 mg/ml for the HBsAg-specific antibody. The relative molecular mass of an IgG molecule is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e142" xlink:type="simple"/></inline-formula> kDa = <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e143" xlink:type="simple"/></inline-formula> g/mol. Therefore there are a maximum of<disp-formula id="pcbi.1003730.e144"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e144" xlink:type="simple"/><label>(23)</label></disp-formula></p>
<p>Hence, we set the HbsAg-specific antibody carrying capacity at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e145" xlink:type="simple"/></inline-formula> molecules per ml. Initially, we assume there are no free or complexed HbsAg-specific antibodies present, <italic>i.e.</italic> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e146" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e147" xlink:type="simple"/></inline-formula>. The IgG subclasses that form immune complexes with HBsAg have half-lives in blood of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e148" xlink:type="simple"/></inline-formula> days <xref ref-type="bibr" rid="pcbi.1003730-Morell1">[49]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Rossi1">[50]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Rath2">[51]</xref>, corresponding to an antibody removal rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e149" xlink:type="simple"/></inline-formula>/day. We do not know the antigen-dependent and -independent antibody growth rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e150" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e151" xlink:type="simple"/></inline-formula> which we estimate through data fitting. We take the virus-antibody dissociation rate to be <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e152" xlink:type="simple"/></inline-formula> per second, or approximately <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e153" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Schwesinger1">[52]</xref>. The IgG affinity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e154" xlink:type="simple"/></inline-formula> in a humoral response frequently starts at <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e155" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Gopalakrishnan1">[53]</xref> and can become as high as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e156" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Roost1">[54]</xref>. For HBV, each virion can have ten to hundreds of potential antibody binding sites and affinity maturation may occur. Taking both effects into account can increase the functional affinity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e157" xlink:type="simple"/></inline-formula> to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e158" xlink:type="simple"/></inline-formula> M<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e159" xlink:type="simple"/></inline-formula>. Therefore, the binding rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e160" xlink:type="simple"/></inline-formula>/day<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e161" xlink:type="simple"/></inline-formula> ml per molecule per day. Below we also consider a model where multiple antibodies can bind each virus particle. The antibody-virus complex clearance rate is taken as four times higher than the clearance of the virus, <italic>i.e</italic>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e162" xlink:type="simple"/></inline-formula>, as has been found for HIV-antibody complexes <xref ref-type="bibr" rid="pcbi.1003730-Igarashi1">[55]</xref>.</p>
<p>There is 100-fold to 100,000-fold excess of noninfectious subviral particles, corresponding to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e163" xlink:type="simple"/></inline-formula>, relative to infectious particles <xref ref-type="bibr" rid="pcbi.1003730-Ganem1">[19]</xref>. We assume that a healthy individual produces an excess of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e164" xlink:type="simple"/></inline-formula> subviral particles. We estimate the remaining parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e165" xlink:type="simple"/></inline-formula> by fitting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e166" xlink:type="simple"/></inline-formula> as given by the antibody model (7) to data from HBV acute infections <xref ref-type="bibr" rid="pcbi.1003730-Webster1">[56]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref> and Table S1. The infection dates for each patient were either known or estimated previously <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Whalley1">[57]</xref>. We use the ‘fminsearch’ and ‘ode15s’ routines in MATLAB R2012a (The MathWorks Inc., Natick, MA). The parameter values are presented in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref>. We then vary <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e167" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e168" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e169" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e170" xlink:type="simple"/></inline-formula> and investigate the results.</p>
<table-wrap id="pcbi-1003730-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.t001</object-id><label>Table 1</label><caption>
<title>Variables, parameters and values used in simulations.</title>
</caption><alternatives><graphic id="pcbi-1003730-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Variables</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e171" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Target cells</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e172" xlink:type="simple"/></inline-formula> per ml</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e173" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Infected cells</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e174" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e175" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Free antibody</td>
<td align="left" rowspan="1" colspan="1">molecules per ml (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e176" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Free virus</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e177" xlink:type="simple"/></inline-formula> per ml</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e178" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Subviral particles</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e179" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Virus-antibody complexes</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e180" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e181" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">Subviral particle-antibody complexes</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Parameters</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e182" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">hepatocyte maximum proliferation rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e183" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e184" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">infectivity rate constant</td>
<td align="left" rowspan="1" colspan="1">ml <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e185" xlink:type="simple"/></inline-formula> (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e186" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">hepatocyte carrying capacity</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e187" xlink:type="simple"/></inline-formula> cells per ml</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e188" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">infected cell killing rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e189" xlink:type="simple"/></inline-formula> (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e190" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">cure rate</td>
<td align="left" rowspan="1" colspan="1">0</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e191" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody production</td>
<td align="left" rowspan="1" colspan="1">molecules <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e192" xlink:type="simple"/></inline-formula> (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e193" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antigen-independent antibody growth rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e194" xlink:type="simple"/></inline-formula> (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e195" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody degradation rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e196" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e197" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody carrying capacity</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e198" xlink:type="simple"/></inline-formula> molecules per ml</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e199" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody binding rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e200" xlink:type="simple"/></inline-formula> ml <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e201" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e202" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody dissociation rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e203" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e204" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">virus production rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e205" xlink:type="simple"/></inline-formula> (varies)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e206" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">virus clearance rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e207" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e208" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">complexes degradation rate</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e209" xlink:type="simple"/></inline-formula></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e210" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">subvirus∶virus ratio</td>
<td align="left" rowspan="1" colspan="1">varies</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e211" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">antibody units conversion factor</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e212" xlink:type="simple"/></inline-formula> mg/molecule</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap><table-wrap id="pcbi-1003730-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.t002</object-id><label>Table 2</label><caption>
<title>Parameter best estimates.</title>
</caption><alternatives><graphic id="pcbi-1003730-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Patient</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e213" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e214" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e215" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e216" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e217" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e218" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e219" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">RSS</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.953</td>
<td align="left" rowspan="1" colspan="1">297</td>
<td align="left" rowspan="1" colspan="1">0.1538</td>
<td align="left" rowspan="1" colspan="1">0.4242</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">4.8</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">11.1</td>
<td align="left" rowspan="1" colspan="1">43.5</td>
<td align="left" rowspan="1" colspan="1">0.061</td>
<td align="left" rowspan="1" colspan="1">0.4656</td>
<td align="left" rowspan="1" colspan="1">0.7</td>
<td align="left" rowspan="1" colspan="1">3.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">18.2</td>
<td align="left" rowspan="1" colspan="1">12.4</td>
<td align="left" rowspan="1" colspan="1">0.018</td>
<td align="left" rowspan="1" colspan="1">0.2672</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">3.5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">8.8</td>
<td align="left" rowspan="1" colspan="1">26.4</td>
<td align="left" rowspan="1" colspan="1">0.064</td>
<td align="left" rowspan="1" colspan="1">0.288</td>
<td align="left" rowspan="1" colspan="1">520</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">6.1</td>
<td align="left" rowspan="1" colspan="1">42.5</td>
<td align="left" rowspan="1" colspan="1">0.049</td>
<td align="left" rowspan="1" colspan="1">0.3578</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">5.87</td>
<td align="left" rowspan="1" colspan="1">28.5</td>
<td align="left" rowspan="1" colspan="1">0.043</td>
<td align="left" rowspan="1" colspan="1">0.29</td>
<td align="left" rowspan="1" colspan="1">1.16</td>
<td align="left" rowspan="1" colspan="1">8.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">113</td>
<td align="left" rowspan="1" colspan="1">0.0000998</td>
<td align="left" rowspan="1" colspan="1">0.4623</td>
<td align="left" rowspan="1" colspan="1">0.41</td>
<td align="left" rowspan="1" colspan="1">6.1</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">median</td>
<td align="left" rowspan="1" colspan="1">6.1</td>
<td align="left" rowspan="1" colspan="1">42.5</td>
<td align="left" rowspan="1" colspan="1">0.049</td>
<td align="left" rowspan="1" colspan="1">0.358</td>
<td align="left" rowspan="1" colspan="1">1.16</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">average</td>
<td align="left" rowspan="1" colspan="1">7.57</td>
<td align="left" rowspan="1" colspan="1">80.5</td>
<td align="left" rowspan="1" colspan="1">0.056</td>
<td align="left" rowspan="1" colspan="1">0.365</td>
<td align="left" rowspan="1" colspan="1">77.3</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">stdev</td>
<td align="left" rowspan="1" colspan="1">5.87</td>
<td align="left" rowspan="1" colspan="1">101</td>
<td align="left" rowspan="1" colspan="1">0.049</td>
<td align="left" rowspan="1" colspan="1">0.085</td>
<td align="left" rowspan="1" colspan="1">195</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>The parameter units are as described in <xref ref-type="table" rid="pcbi-1003730-t001">Table 1</xref>.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b2">
<title>Virus dynamics</title>
<p>In the absence of antibody responses <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e220" xlink:type="simple"/></inline-formula>, corresponding to established, chronic HBV infection in model (1). We investigate how these dynamics change in the presence of antibody and an excess of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e221" xlink:type="simple"/></inline-formula> subviral particles.</p>
<p>We fitted <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e222" xlink:type="simple"/></inline-formula> as given by the antibody model (7) to data from seven individuals, who were identified in the acute stage of infection during a single-source HBV outbreak (for details see <xref ref-type="bibr" rid="pcbi.1003730-Webster1">[56]</xref>). The results are presented in <xref ref-type="fig" rid="pcbi-1003730-g001">Fig. 1</xref> and the best parameter estimates for each patient are presented in <xref ref-type="table" rid="pcbi-1003730-t002">Table 2</xref>. The model matches the high viral peak observed during each patients' acute infection phase, and the biphasic viral decay from the peak. Moreover, the best estimates predict that virus clearance (defined as less than one virion in the body) occurs following infection in the first six patients and does not occur in patient 7 (who is known to have developed chronic infections). Although the model fits the virus data, it predicts that free antibody levels are much higher than those observed in unvaccinated patients. We will show in section 4.4 how addition of a cell-mediated immune response allows for viral clearance with lower antibody concentrations.</p>
<fig id="pcbi-1003730-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g001</object-id><label>Figure 1</label><caption>
<title>The best fit of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e223" xlink:type="simple"/></inline-formula> as given by model (7) (solid lines) to patient data (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e224" xlink:type="simple"/></inline-formula>).</title>
<p>Best parameter estimates are presented in <xref ref-type="table" rid="pcbi-1003730-t002">Table 2</xref>. The other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Table 1</xref>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g001" position="float" xlink:type="simple"/></fig>
<p>We did not find any correlation between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e225" xlink:type="simple"/></inline-formula> and the time to clearance, however the fast clearance time noticed in patient 1 corresponds to a steep second phase viral decay due to a high loss rate of infected cells, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e226" xlink:type="simple"/></inline-formula>. Conversely, patients 3 and 7, who have the smallest <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e227" xlink:type="simple"/></inline-formula>, experience the longest time until viral clearance and no clearance, respectively.</p>
<p>The parameter estimates for the first six patients satisfy the condition <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e228" xlink:type="simple"/></inline-formula> corresponding to asymptotic stability of the cleared infection steady state. Moreover, if <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e229" xlink:type="simple"/></inline-formula> the cleared infection steady state becomes unstable and either a stable chronic steady state or a limit cycle emerge (<xref ref-type="fig" rid="pcbi-1003730-g002">Fig. 2</xref>).</p>
<fig id="pcbi-1003730-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g002</object-id><label>Figure 2</label><caption>
<title>Dynamics of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e230" xlink:type="simple"/></inline-formula> as given by model (7) when the cleared infection condition (19) fails.</title>
<p>Parameter values are as in <xref ref-type="table" rid="pcbi-1003730-t001">Table 1</xref> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e231" xlink:type="simple"/></inline-formula> molecules per ml, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e232" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e233" xlink:type="simple"/></inline-formula> ml per virus per day, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e234" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e235" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e236" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e237" xlink:type="simple"/></inline-formula> per infected cell per day (panel a); <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e238" xlink:type="simple"/></inline-formula> per infected cell per day (panel b).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g002" position="float" xlink:type="simple"/></fig>
<p>We next assume that all parameters values are fixed at the median best fit values given in <xref ref-type="table" rid="pcbi-1003730-t002">Table 2</xref>, which satisfy the clearance conditions (19), and we investigate how the virus dynamics change when we vary four bifurcation parameters: the constant of proportionality <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e239" xlink:type="simple"/></inline-formula>, the antigen-independent and -dependent antibody growth rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e240" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e241" xlink:type="simple"/></inline-formula>, and the initial antibody concentration <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e242" xlink:type="simple"/></inline-formula>. As <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e243" xlink:type="simple"/></inline-formula> increases it reaches a threshold value <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e244" xlink:type="simple"/></inline-formula> such that for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e245" xlink:type="simple"/></inline-formula> virus is cleared and the antibody reaches its carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e246" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1003730-g003">Fig. 3</xref>). For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e247" xlink:type="simple"/></inline-formula> a chronic steady state value emerges which co-exists and is bistable with the cleared infection steady state (<xref ref-type="fig" rid="pcbi-1003730-g004">Fig. 4</xref>). In the bistable parameter space viral clearance is reached asymptotically when the antigen-independent antibody growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e248" xlink:type="simple"/></inline-formula> is increased (see <xref ref-type="fig" rid="pcbi-1003730-g005">Fig. 5</xref> left panel) or when initial antibody levels are increased (see <xref ref-type="fig" rid="pcbi-1003730-g005">Fig. 5</xref> right panel). Similar results are obtained when the antigen-dependent growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e249" xlink:type="simple"/></inline-formula> is increased (<xref ref-type="supplementary-material" rid="pcbi.1003730.s002">Fig. S1</xref> in <xref ref-type="supplementary-material" rid="pcbi.1003730.s006">Text S1</xref>).</p>
<fig id="pcbi-1003730-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g003</object-id><label>Figure 3</label><caption>
<title>Free antibody at steady state as given by model (7) as a function of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e250" xlink:type="simple"/></inline-formula>.</title>
<p>The other parameters are as <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values). Note that for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e251" xlink:type="simple"/></inline-formula>, the antibody reaches its carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e252" xlink:type="simple"/></inline-formula>. For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e253" xlink:type="simple"/></inline-formula> the infection is not cleared and the maximum antibody value is less than the carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e254" xlink:type="simple"/></inline-formula>.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g003" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003730-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g004</object-id><label>Figure 4</label><caption>
<title>Stable steady state solutions for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e255" xlink:type="simple"/></inline-formula> as given by model (7) as a function of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e256" xlink:type="simple"/></inline-formula>.</title>
<p>The other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values). Notice bistability between the chronic and the cleared infection steady states occurs when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e257" xlink:type="simple"/></inline-formula>. The cleared infection steady state is reached for all <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e258" xlink:type="simple"/></inline-formula> when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e259" xlink:type="simple"/></inline-formula> molecules per ml.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g004" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003730-g005" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g005</object-id><label>Figure 5</label><caption>
<title>Free virus dynamics as given by model (7) and parameters in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values):</title>
<p>The asymptotically stable cleared infection steady state is approached for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e260" xlink:type="simple"/></inline-formula> (red line, both panels); bistable dynamics is observed for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e261" xlink:type="simple"/></inline-formula> with (left panel): Viral clearance for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e262" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e263" xlink:type="simple"/></inline-formula> (dashed blue line) and viral persistence for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e264" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e265" xlink:type="simple"/></inline-formula> (solid blue line); (right panel): Viral clearance is observed for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e266" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e267" xlink:type="simple"/></inline-formula> molecules per ml (dashed blue line) and viral persistence for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e268" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e269" xlink:type="simple"/></inline-formula> molecules per ml (solid blue line).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g005" position="float" xlink:type="simple"/></fig>
<p>The antibody model (7) assumed that when one antibody binds a virus with a certain avidity the virus will be neutralized. Since HBV has multiple surface proteins, each of them can potentially facilitate infection. This situation has been described in HIV viral infection where even as little as one functional gp160 (surface protein) may be sufficient to promote virus entry <xref ref-type="bibr" rid="pcbi.1003730-Klasse1">[58]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Yang1">[59]</xref>. We investigate the changes in the dynamics of model (7) if we incorporate binding to multiple surface proteins into model (7) as follows. Let <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e270" xlink:type="simple"/></inline-formula> be the concentration of virus with with no antibody bound and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e271" xlink:type="simple"/></inline-formula> be the concentration of virus with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e272" xlink:type="simple"/></inline-formula> surface antigens bound by antibody, with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e273" xlink:type="simple"/></inline-formula>, where we assume <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e274" xlink:type="simple"/></inline-formula> is the maximum number of antibodies that can simultaneously bind a virion. When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e275" xlink:type="simple"/></inline-formula> encounters an antibody, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e276" xlink:type="simple"/></inline-formula>, there are <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e277" xlink:type="simple"/></inline-formula> ways to occupy one of its surface proteins and obtain a virion with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e278" xlink:type="simple"/></inline-formula> occupied sites, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e279" xlink:type="simple"/></inline-formula>. The reaction kinetics can be represented schematically as follows<disp-formula id="pcbi.1003730.e280"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e280" xlink:type="simple"/><label>(24)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e281" xlink:type="simple"/></inline-formula>. As before, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e282" xlink:type="simple"/></inline-formula> is the rate constant for binding between the antibody and a viral surface antigen and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e283" xlink:type="simple"/></inline-formula> is the disassociation rate. We consider that the virus-antibody complexes are cleared at a rate proportional to the number of bound antibodies, <italic>i.e.</italic>,<disp-formula id="pcbi.1003730.e284"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e284" xlink:type="simple"/><label>(25)</label></disp-formula>or the effects of antibody binding on clearance saturate, <italic>i.e.</italic>,<disp-formula id="pcbi.1003730.e285"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e285" xlink:type="simple"/><label>(26)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e286" xlink:type="simple"/></inline-formula> is a hill coefficient, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e287" xlink:type="simple"/></inline-formula> is the maximum increase in clearance that can be obtained by antibody binding, and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e288" xlink:type="simple"/></inline-formula> is the number of bound antibodies needed to generate a half-maximal effect. Moreover, we assume that the virus-antibody complexes infectivity rates decrease with the number of bound antibodies <xref ref-type="bibr" rid="pcbi.1003730-Klasse1">[58]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Magnus1">[60]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Magnus2">[61]</xref>. Lastly, the SVPs with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e289" xlink:type="simple"/></inline-formula> surface antigens bound by antibody are proportional with the virus with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e290" xlink:type="simple"/></inline-formula> bound antibodies, <italic>i.e.</italic> <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e291" xlink:type="simple"/></inline-formula>. System (7) becomes<disp-formula id="pcbi.1003730.e292"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e292" xlink:type="simple"/><label>(27)</label></disp-formula>where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e293" xlink:type="simple"/></inline-formula> and the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e294" xlink:type="simple"/></inline-formula> terms are included to account for the antibody binding to SVPs. The total HBV virus is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e295" xlink:type="simple"/></inline-formula>, the total immune complexes is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e296" xlink:type="simple"/></inline-formula> and the total antibody is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e297" xlink:type="simple"/></inline-formula>. We will refer to system (27) as the multivalent binding model.</p>
<p>It has been reported that quasispherical SVP contain 48 HBsAg dimers <xref ref-type="bibr" rid="pcbi.1003730-Patient1">[23]</xref> and we assumed that virions have the same HBsAg numbers. We compared the dynamics of virus and antibody-virus complexes as given by the multivalent binding model (27) for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e298" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e299" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e300" xlink:type="simple"/></inline-formula> given by (25) or (26) with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e301" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e302" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e303" xlink:type="simple"/></inline-formula>. To preserve the avidity of the antibody we normalize the binding and unbinding parameters so that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e304" xlink:type="simple"/></inline-formula> is constant. For <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e305" xlink:type="simple"/></inline-formula> we assume <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e306" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e307" xlink:type="simple"/></inline-formula>. Numerical results show that the exponential growth to the peak and the rates of first and second phase decay of both virus and total virus-antibody complexes are similar regardless of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e308" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1003730-g006">Fig. 6</xref>). However, the overall levels of free virus and total antigen-antibody complexes during the second phase decay decrease for high <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e309" xlink:type="simple"/></inline-formula> due to faster clearance of immune complexes for both forms of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e310" xlink:type="simple"/></inline-formula> (<xref ref-type="fig" rid="pcbi-1003730-g006">Fig. 6</xref>).</p>
<fig id="pcbi-1003730-g006" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g006</object-id><label>Figure 6</label><caption>
<title>Free virus <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e311" xlink:type="simple"/></inline-formula> (solid lines) and total complexes <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e312" xlink:type="simple"/></inline-formula> (dashed lines) as given by model (27) for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e313" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e314" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e315" xlink:type="simple"/></inline-formula> given by (25) (black and magenta lines) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e316" xlink:type="simple"/></inline-formula> given by (26) with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e317" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e318" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e319" xlink:type="simple"/></inline-formula> (red and blue lines).</title>
<p>The binding and unbinding rates are normalized so that <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e320" xlink:type="simple"/></inline-formula> is constant. The other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g006" position="float" xlink:type="simple"/></fig></sec><sec id="s3b3">
<title>Antibody dynamics</title>
<p>We investigated the dynamics of free antibodies, virus-antibody and subviral particle-antibody complexes for the antibody model (7) and the median parameter values given in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> and various values of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e321" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e322" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e323" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e324" xlink:type="simple"/></inline-formula>. We present antibody concentrations in mg per ml by multiplying the antibody values obtained in simulations by a factor <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e325" xlink:type="simple"/></inline-formula> which transforms molecules/ml to mg/ml, and takes into account the molecular weight of IgG.</p>
<p>To understand the role of subviral particles, we first examine system (7)'s dynamics when the ratio of subviral particles to virus is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e326" xlink:type="simple"/></inline-formula> and the clearance condition (19) holds. As shown in <xref ref-type="fig" rid="pcbi-1003730-g007">Fig. 7</xref>, left panel, the HBsAg-specific antibody concentration is small, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e327" xlink:type="simple"/></inline-formula> mg/ml at day 82, when the virus is at its maximum. Antibody concentration continued to increase and reached its carrying capacity of 1 mg/ml two months after the virus peak, which is higher than reported in unvaccinated patients (<xref ref-type="fig" rid="pcbi-1003730-g007">Fig. 7</xref> left panel).</p>
<fig id="pcbi-1003730-g007" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g007</object-id><label>Figure 7</label><caption>
<title>Free antibody (red lines), virus-antibody complexes (solid blue lines) and subviral particles-antibody complexes (dashed blue lines) in mg/ml as given by model (7) and parameters in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values) for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e328" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e329" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e330" xlink:type="simple"/></inline-formula> (left panel); <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e331" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e332" xlink:type="simple"/></inline-formula> mg/ml, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e333" xlink:type="simple"/></inline-formula> (middle panel); <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e334" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e335" xlink:type="simple"/></inline-formula> mg/ml, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e336" xlink:type="simple"/></inline-formula> (right panel).</title>
<p>The dotted black line represents the antibody limit of detection of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e337" xlink:type="simple"/></inline-formula> ng/ml and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e338" xlink:type="simple"/></inline-formula> is the factor transforming the units from molecules/ml to mg/ml.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g007" position="float" xlink:type="simple"/></fig>
<p>When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e339" xlink:type="simple"/></inline-formula> bistable dynamics emerge. When there are no pre-existing antibodies, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e340" xlink:type="simple"/></inline-formula>, the antibody is inefficient in controlling the virus. Even though free antibodies reach a maximum value of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e341" xlink:type="simple"/></inline-formula> mg/ml three weeks before the viral peak, this equilibrium value is seven-order magnitude smaller than the antibody carrying capacity. This reduction in free antibody is due to the presence of subviral particles, which bind antibody and are rapidly cleared. Because of low antibody concentration and the rapid clearance of subviral particles the peak concentrations of virus-antibody and subviral particle-antibody complexes are also small, <italic>i.e.</italic>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e342" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e343" xlink:type="simple"/></inline-formula> mg/ml, respectively (<xref ref-type="fig" rid="pcbi-1003730-g007">Fig. 7</xref> middle panel), below the antibody's limit of detection of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e344" xlink:type="simple"/></inline-formula> ng/ml <xref ref-type="bibr" rid="pcbi.1003730-IgG1">[62]</xref>. Moreover, virus clearance does not occur because the high level of subviral particles serve as a decoy binding the initially low number of antibodies. This leaves a window of opportunity for viral persistence.</p>
<p>When <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e345" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e346" xlink:type="simple"/></inline-formula> molecules/ml (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e347" xlink:type="simple"/></inline-formula> mg/ml) we recover the same dynamics for virus, antibody and virus-antibody complexes as seen in the <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e348" xlink:type="simple"/></inline-formula> case together with subviral particle-antibody complexes levels five orders of magnitude higher than those of virus-antibody complexes (<xref ref-type="fig" rid="pcbi-1003730-g007">Fig. 7</xref> right panel).</p>
<p>The antibody model (7) assumed that B-cell priming by the virus is followed by an antigen-independent antibody expansion with a maximum per capita growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e349" xlink:type="simple"/></inline-formula>. This was one of the parameters that we fitted to the data and obtained estimates ranging between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e350" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e351" xlink:type="simple"/></inline-formula>. To determine how the dynamics of the antibody model (7) change if we vary <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e352" xlink:type="simple"/></inline-formula>, we kept all the other parameters fixed at the median values in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> and assumed <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e353" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e354" xlink:type="simple"/></inline-formula>. As seen in <xref ref-type="fig" rid="pcbi-1003730-g008">Fig. 8</xref>, the virus is cleared when the antibody growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e355" xlink:type="simple"/></inline-formula> is high. However, as <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e356" xlink:type="simple"/></inline-formula> decreases the time to viral clearance increases until, eventually, the virus cannot be controlled and chronic infection occurs (<xref ref-type="fig" rid="pcbi-1003730-g008">Fig. 8</xref>, dotted lines). The chronicity can be reversed when the initial antibody level is increased (<xref ref-type="fig" rid="pcbi-1003730-g009">Fig. 9</xref>, right panel), as occurs after vaccination. Similar dynamics are seen when the antigen-dependent antibody growth rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e357" xlink:type="simple"/></inline-formula> is varied.</p>
<fig id="pcbi-1003730-g008" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g008</object-id><label>Figure 8</label><caption>
<title>Free virus per ml (left panel); free antibody (red lines) and virus-antibody complexes (blue lines) in mg/ml (right panel) for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e358" xlink:type="simple"/></inline-formula> (solid lines); <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e359" xlink:type="simple"/></inline-formula> (dashed lines) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e360" xlink:type="simple"/></inline-formula> (dotted lines).</title>
<p>The other parameters are as <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g008" position="float" xlink:type="simple"/></fig><fig id="pcbi-1003730-g009" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g009</object-id><label>Figure 9</label><caption>
<title>Stable steady state solutions for free virus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e361" xlink:type="simple"/></inline-formula>, as given by model (7), for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e362" xlink:type="simple"/></inline-formula> as a function of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e363" xlink:type="simple"/></inline-formula> when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e364" xlink:type="simple"/></inline-formula> (left panel), and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e365" xlink:type="simple"/></inline-formula> when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e366" xlink:type="simple"/></inline-formula> (right panel).</title>
<p>The other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g009" position="float" xlink:type="simple"/></fig>
<p>We assumed that the antibody parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e367" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e368" xlink:type="simple"/></inline-formula> are unknown. By calculating the relative sensitivity equations with respect to <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e369" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e370" xlink:type="simple"/></inline-formula> <xref ref-type="bibr" rid="pcbi.1003730-Bortz1">[63]</xref>, we find that the effects of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e371" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e372" xlink:type="simple"/></inline-formula> on the virus, antibody and virus-antibody complexes are proportional at each time point (<xref ref-type="supplementary-material" rid="pcbi.1003730.s004">Fig. S3</xref> in <xref ref-type="supplementary-material" rid="pcbi.1003730.s006">Text S1</xref>). Therefore fixing one and fitting the other will preserve virus-antibody dynamics. The combined effects of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e373" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e374" xlink:type="simple"/></inline-formula> on the virus steady state are presented in <xref ref-type="supplementary-material" rid="pcbi.1003730.s002">Fig. S1</xref> in <xref ref-type="supplementary-material" rid="pcbi.1003730.s006">Text S1</xref>. Moreover, the model long-term's outcomes do not change when the antibody affinity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e375" xlink:type="simple"/></inline-formula> is constant, but the relative <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e376" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e377" xlink:type="simple"/></inline-formula> values vary within reasonable ranges (not shown).</p>
<p>Because <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e378" xlink:type="simple"/></inline-formula> is a surrogate for the B cell growth rate and is also an important parameter in determining whether viral clearance or chronicity occurs, we investigated the changes in our results when we expand the antibody model (7) to include the dynamics of activated (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e379" xlink:type="simple"/></inline-formula>) and memory (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e380" xlink:type="simple"/></inline-formula>) B cells. We assume that activated B cells expand at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e381" xlink:type="simple"/></inline-formula> proportional to viral and subviral concentrations, die at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e382" xlink:type="simple"/></inline-formula>, and become memory cells at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e383" xlink:type="simple"/></inline-formula>. Memory cells are maintained through antigen-independent homeostatic proliferation with a maximum difference between proliferation and loss rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e384" xlink:type="simple"/></inline-formula>, and carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e385" xlink:type="simple"/></inline-formula>. Antibody is produced at rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e386" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e387" xlink:type="simple"/></inline-formula> by naive and memory B cells, respectively and is eliminated at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e388" xlink:type="simple"/></inline-formula>. The virus-antibody complex formation is identical to that of model (7). The expanded model (called the B cell activation model),<disp-formula id="pcbi.1003730.e389"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e389" xlink:type="simple"/><label>(28)</label></disp-formula>has essentially the same dynamics as the antibody model (7). Indeed, viral clearance occurs when<disp-formula id="pcbi.1003730.e390"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e390" xlink:type="simple"/><label>(29)</label></disp-formula></p>
<p>Moreover, bistability between the cleared and the chronic infection steady states emerges when <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e391" xlink:type="simple"/></inline-formula> is high and virus clearance occurs when initial antibody levels <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e392" xlink:type="simple"/></inline-formula> or antibody production rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e393" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e394" xlink:type="simple"/></inline-formula> are increased (not shown).</p>
</sec><sec id="s3b4">
<title>Model of combined antibody and cellular immune responses</title>
<p>In our study of the antibody model (7) and its variants, we found that we can describe the data, including the transient nature of primary HBV infection, by the effect of antibodies. However, in every case, a large concentration of antibodies was needed relatively early, reflected for example in a high initial level (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e395" xlink:type="simple"/></inline-formula>), a fast growth rate (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e396" xlink:type="simple"/></inline-formula>) of antibodies, a high affinity (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e397" xlink:type="simple"/></inline-formula>), or a high antibody carrying capacity (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e398" xlink:type="simple"/></inline-formula>). But in clinical practice, antibodies are not detectable until the virus is well on its way to being cleared. Thus, it is possible that another mechanism of control needs to be included. We now investigate this by expanding model (7) to include the effects of effector CD8 T-cells (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e399" xlink:type="simple"/></inline-formula>), along the lines of our previous work <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>.</p>
<p>We assume that in the absence of infection there is a basal level of HBV-specific immune effector cells given by <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e400" xlink:type="simple"/></inline-formula>, where <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e401" xlink:type="simple"/></inline-formula> are CD8 T cells specific for HBV-infected cells and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e402" xlink:type="simple"/></inline-formula> is their average lifespan. Upon encounter with antigen CD8 T cells are activated, clonally expand, and differentiate into true effector cells at rate <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e403" xlink:type="simple"/></inline-formula>. We assume that there is a time delay, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e404" xlink:type="simple"/></inline-formula>, between antigen encounter and effector cell expansion as in <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. Infected cells can be killed by the immune response at a rate of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e405" xlink:type="simple"/></inline-formula> per cell. The new CD8-antibody model is<disp-formula id="pcbi.1003730.e406"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pcbi.1003730.e406" xlink:type="simple"/><label>(30)</label></disp-formula>with <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e407" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e408" xlink:type="simple"/></inline-formula> cells per day, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e409" xlink:type="simple"/></inline-formula> per day and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e410" xlink:type="simple"/></inline-formula> per infected cells per day as in <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. Moreover, we assume that the free and bound virus is cleared at rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e411" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e412" xlink:type="simple"/></inline-formula> per day. The antibody binding rate is <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e413" xlink:type="simple"/></inline-formula> per molecules per day, two-fold higher than in the antibody model (7) and the antibody carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e414" xlink:type="simple"/></inline-formula> is four-fold lower than in the antibody model (7). This allows for a higher antibody affinity that can control the infection even at low equilibrium antibody levels. As before, a healthy individual produces an excess of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e415" xlink:type="simple"/></inline-formula> subviral particles. We assume that the delay in the expansion of effector cells is kept at values given in <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>, <italic>i.e.</italic>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e416" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e417" xlink:type="simple"/></inline-formula>, and estimate the remaining parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e418" xlink:type="simple"/></inline-formula> by fitting <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e419" xlink:type="simple"/></inline-formula> to data from HBV acute infections <xref ref-type="bibr" rid="pcbi.1003730-Webster1">[56]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. The estimates are presented in <xref ref-type="table" rid="pcbi-1003730-t003">Table 3</xref> and the free virus and free antibody are presented in <xref ref-type="fig" rid="pcbi-1003730-g010">Fig. 10</xref> (red and green lines, respectively). We note that due to the complexity of the CD8-antibody model, the estimates obtained (with Matlab's ‘fminsearch’, as before) are consistent with the data, but we do not claim a unique solution, since for example we fixed many of the parameters as described.</p>
<fig id="pcbi-1003730-g010" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.g010</object-id><label>Figure 10</label><caption>
<title>The viral load (red lines) and free antibody (green lines) predicted by model (30).</title>
<p>The dotted line represents the antibody limit of detection of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e420" xlink:type="simple"/></inline-formula> ng per mL. Best parameter estimates are presented in <xref ref-type="table" rid="pcbi-1003730-t003">Table 3</xref>. <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e421" xlink:type="simple"/></inline-formula> per molecule per day, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e422" xlink:type="simple"/></inline-formula> molecules per mL, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e423" xlink:type="simple"/></inline-formula> per day, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e424" xlink:type="simple"/></inline-formula> per day and the other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Table 1</xref>. Patient data is represented by blue symbols.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.g010" position="float" xlink:type="simple"/></fig><table-wrap id="pcbi-1003730-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1003730.t003</object-id><label>Table 3</label><caption>
<title>Estimated parameters found by fitting model (30) to data.</title>
</caption><alternatives><graphic id="pcbi-1003730-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1003730.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Patient</td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e425" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e426" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e427" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e428" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e429" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e430" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e431" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1"><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e432" xlink:type="simple"/></inline-formula><inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e433" xlink:type="simple"/></inline-formula></td>
<td align="left" rowspan="1" colspan="1">RSS</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2.54</td>
<td align="left" rowspan="1" colspan="1">266.8</td>
<td align="left" rowspan="1" colspan="1">0.11</td>
<td align="left" rowspan="1" colspan="1">0.31</td>
<td align="left" rowspan="1" colspan="1">8.8</td>
<td align="left" rowspan="1" colspan="1">2.1</td>
<td align="left" rowspan="1" colspan="1">4.99</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">9.24</td>
<td align="left" rowspan="1" colspan="1">117.1</td>
<td align="left" rowspan="1" colspan="1">0.035</td>
<td align="left" rowspan="1" colspan="1">0.29</td>
<td align="left" rowspan="1" colspan="1">5.9</td>
<td align="left" rowspan="1" colspan="1">2.5</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">6.23</td>
<td align="left" rowspan="1" colspan="1">159.4</td>
<td align="left" rowspan="1" colspan="1">0.071</td>
<td align="left" rowspan="1" colspan="1">0.24</td>
<td align="left" rowspan="1" colspan="1">13.8</td>
<td align="left" rowspan="1" colspan="1">0.6</td>
<td align="left" rowspan="1" colspan="1">3.27</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">4.9</td>
<td align="left" rowspan="1" colspan="1">365.5</td>
<td align="left" rowspan="1" colspan="1">0.146</td>
<td align="left" rowspan="1" colspan="1">0.45</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2.43</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">4.95</td>
<td align="left" rowspan="1" colspan="1">186.7</td>
<td align="left" rowspan="1" colspan="1">0.082</td>
<td align="left" rowspan="1" colspan="1">0.41</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">0.6</td>
<td align="left" rowspan="1" colspan="1">3.33</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">2.21</td>
<td align="left" rowspan="1" colspan="1">327.3</td>
<td align="left" rowspan="1" colspan="1">0.073</td>
<td align="left" rowspan="1" colspan="1">0.22</td>
<td align="left" rowspan="1" colspan="1">1.5</td>
<td align="left" rowspan="1" colspan="1">0.5</td>
<td align="left" rowspan="1" colspan="1">7.14</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">2.6</td>
<td align="left" rowspan="1" colspan="1">305</td>
<td align="left" rowspan="1" colspan="1">0.018</td>
<td align="left" rowspan="1" colspan="1">0.35</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">0.1</td>
<td align="left" rowspan="1" colspan="1">6.9</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">median</td>
<td align="left" rowspan="1" colspan="1">4.85</td>
<td align="left" rowspan="1" colspan="1">266</td>
<td align="left" rowspan="1" colspan="1">0.073</td>
<td align="left" rowspan="1" colspan="1">0.31</td>
<td align="left" rowspan="1" colspan="1">1.5</td>
<td align="left" rowspan="1" colspan="1">0.6</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">average</td>
<td align="left" rowspan="1" colspan="1">4.65</td>
<td align="left" rowspan="1" colspan="1">246</td>
<td align="left" rowspan="1" colspan="1">0.076</td>
<td align="left" rowspan="1" colspan="1">0.32</td>
<td align="left" rowspan="1" colspan="1">4.4</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">stdev</td>
<td align="left" rowspan="1" colspan="1">2.53</td>
<td align="left" rowspan="1" colspan="1">93</td>
<td align="left" rowspan="1" colspan="1">0.042</td>
<td align="left" rowspan="1" colspan="1">0.08</td>
<td align="left" rowspan="1" colspan="1">5.3</td>
<td align="left" rowspan="1" colspan="1">0.9</td>
<td align="left" rowspan="1" colspan="1">-</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap>
<p>In the CD8-antibody model, the cellular immune responses are responsible for the initial virus decay and antibodies that bind virus with high affinity, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e434" xlink:type="simple"/></inline-formula> molecules per mL (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e435" xlink:type="simple"/></inline-formula>) control the second phase decay and prevent virus rebound (<xref ref-type="fig" rid="pcbi-1003730-g010">Fig. 10</xref> red lines, first six patients). This result holds even though the overall antibody level is small, with free antibody growing above the limit of detection <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e436" xlink:type="simple"/></inline-formula> days after infection and reaching an equilibrium of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e437" xlink:type="simple"/></inline-formula> mg per mL, four-fold lower than in model (7) (<xref ref-type="fig" rid="pcbi-1003730-g010">Fig. 10</xref> green lines, first six patients).</p>
<p>When both the antibody production rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e438" xlink:type="simple"/></inline-formula>, and the CD8 T cell killing rate, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e439" xlink:type="simple"/></inline-formula>, are small (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e440" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e441" xlink:type="simple"/></inline-formula> times smaller than the average values among the patients), model (30) predicts virus rebound (<xref ref-type="fig" rid="pcbi-1003730-g010">Fig. 10</xref> red line, patient 7) and low levels of free antibody (<xref ref-type="fig" rid="pcbi-1003730-g010">Fig. 10</xref> green line, patient 7).</p>
<p>Therefore, virus clearance can be obtained for high equilibrium antibody levels alone, or for low equilibrium antibody levels combined with a potent cellular immune response.</p>
</sec></sec></sec><sec id="s4">
<title>Discussion</title>
<p>We developed a set of mathematical models of the antibody response to hepatitis B viral infection and tested whether viral clearance is possible in the presence of an excess number of subviral particles. Subviral particles are non-infectious but have HBsAg on their surface and thus bind anti-HBV antibody. If they bind enough anti-HBV antibody they have the potential to counter the antibody response. We used the models and data from seven acutely infected patients to determine important parameters that describe virus and antibody dynamics.</p>
<p>Models of HIV have considered the antibody's effect on virus indirectly by modeling opsonization through enhanced viral clearance and neutralization through decreased virus infectivity <xref ref-type="bibr" rid="pcbi.1003730-Tabei1">[64]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Tomaras1">[65]</xref>. Others considered in detail the interaction between virus and antibody that leads to complex formation <xref ref-type="bibr" rid="pcbi.1003730-Tabei1">[64]</xref>. Here, for the case of HBV, we modeled complex formation between antibody and both viral and subviral particles. This antibody model suggests that viral clearance is highly dependent on the characteristics of the antibody response: equilibrium antibody level, affinity, antigen-dependent and -independent antibody growth rates.</p>
<p>The antibody model (7) predicts that, for the same antibody dynamics, virus clearance can occur for low SVP∶virus ratios but not for high SVP∶virus ratios. However, viral clearance can be achieved regardless of the SVP∶virus ratio if enough HBsAg-specific antibody is present at the time of infection or the antigen-dependent/-independent antibody growth rate is high enough. If we consider, as in clinical observations, that a healthy individual who produces an excess of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e442" xlink:type="simple"/></inline-formula>-particles very likely clears the infection, than virus clearance occurs in the absence of pre-existent antibody when the antibody population's doubling time is faster than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e443" xlink:type="simple"/></inline-formula> days (<xref ref-type="fig" rid="pcbi-1003730-g009">Fig. 9</xref> left panel). Moreover, the virus can still be cleared for slow antibody expansion if vaccine induced antibodies are present at the time of infection <xref ref-type="bibr" rid="pcbi.1003730-Hadler1">[66]</xref>. It is thought that following hepatitis B vaccination and boosting, patients with anti-HBsAg levels of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e444" xlink:type="simple"/></inline-formula> mIU/ml (<inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e445" xlink:type="simple"/></inline-formula> mg/ml) or higher are protected from infection <xref ref-type="bibr" rid="pcbi.1003730-McMahon1">[67]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-McMahon2">[68]</xref>, <xref ref-type="bibr" rid="pcbi.1003730-Cejka1">[69]</xref>. In our study, if we assume an antibody population's doubling time of 16.6 days, the presence of HBsAg-specific antibody levels higher than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e446" xlink:type="simple"/></inline-formula> mg/ml leads to virus clearance (<xref ref-type="fig" rid="pcbi-1003730-g009">Fig. 9</xref> right panel).</p>
<p>We assumed that the antibody's carrying capacity is fixed at the maximum antibody levels observed after vaccination and boosting. Moreover, we assumed that the initial inoculum is low and fixed among all patients. Under these conditions we obtained virus clearance in the absence of pre-existent antibody in six out of seven patients. The predicted antibody levels needed for clearance, however, are higher than observed clinically in unvaccinated individuals, where free antibodies are usually only detected after HBV is nearly cleared. If the predicted free antibody levels are decreased substantially (through decrease of activation parameters <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e447" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e448" xlink:type="simple"/></inline-formula> or through decrease of the carrying capacity <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e449" xlink:type="simple"/></inline-formula>) then pre-existent antibodies are required for protection (<xref ref-type="supplementary-material" rid="pcbi.1003730.s002">Figs. S1</xref> and <xref ref-type="supplementary-material" rid="pcbi.1003730.s003">S2</xref> in <xref ref-type="supplementary-material" rid="pcbi.1003730.s006">Text S1</xref>).</p>
<p>The antibody model (7) predicts that more than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e450" xlink:type="simple"/></inline-formula> of hepatocytes are infected at the peak of acute infection, lower than previously estimated <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. These cells are replaced through homeostasis and the maximum liver loss at any one time ranges between <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e451" xlink:type="simple"/></inline-formula>. The length of time the continuous liver death and replacement occurs is dependent on the antibody dynamics, such as the antigen-dependent and -independent growth rates <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e452" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e453" xlink:type="simple"/></inline-formula>, and the initial values, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e454" xlink:type="simple"/></inline-formula>. Rapid liver cell turnover can lead to accumulation of mutations in the host genome that could result in genetic alterations, chromosomal rearrangements, activation of oncogenes, inactivation of tumor suppressor genes, and ultimately to hepatocellular carcinoma as seen in many patients with chronic hepatitis <xref ref-type="bibr" rid="pcbi.1003730-Parkin1">[70]</xref>.</p>
<p>Model (7) assumed that one antibody is sufficient to neutralize a virion. We relaxed this assumption by developing a multivalent model (27) that accounted for multiple binding events. We tested whether the observed dynamics change when multiple antibodies bind a virion and consequently lower virus infectivity and/or enhance virus clearance. We found that such antiviral activity has an effect on the size (but not the shape) of free and bound virus during the second phase decay but not on viral peak (<xref ref-type="fig" rid="pcbi-1003730-g006">Fig. 6</xref>). Another antiviral response that we tested was the effect of increasing the ratio between the clearance of immune complexes and that of free virus. Originally we assumed that the immune complexes are cleared four times faster than the free virus, as in HIV <xref ref-type="bibr" rid="pcbi.1003730-Igarashi1">[55]</xref>. In the virus clearance region, an increase in this ratio led to the decrease of free virus during the second phase decay (<xref ref-type="supplementary-material" rid="pcbi.1003730.s005">Fig. S4</xref> in <xref ref-type="supplementary-material" rid="pcbi.1003730.s006">Text S1</xref>).</p>
<p>An unresolved issue is whether the assay used to measure patients HBV levels (the Amplicor HBV Monitor Test <xref ref-type="bibr" rid="pcbi.1003730-Whalley1">[57]</xref>) measures only free virus, as we assumed, or both HBV DNA in free virus and immune complexes. In this regard, the patient HBV DNA was recovered from serum samples by a chemical denaturant method <xref ref-type="bibr" rid="pcbi.1003730-Webster1">[56]</xref>, which has lower yield than techniques that use both chemical methods and proteolytic enzymes <xref ref-type="bibr" rid="pcbi.1003730-Read1">[71]</xref>. The latter should be more efficient at breaking apart virus-antibody complexes.</p>
<p>We compared the estimates for the other parameters with those from our previous hepatitis B study that used the same patient data <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. We found that the median infectivity rate is higher, and the viral production rate is smaller in the antibody model (7). Our best estimates predict viral clearance in the first six patients and viral persistence in patient 7. This is consistent with clinical results which report that patient 7 was immunosuppressed and developed chronic disease. Data fitting shows that he has the lowest infected cell clearance rates. The antibody model (7) shows that in order for the virus to be cleared this patient would need to have one or a combination of the following: (1) low subviral particles production together with a high pre-existing antibody level; (2) antibody of high affinity; (3) high antigen-dependent and/or -independent antibody growth; (4) increased clearance of virus-antibody complexes; (5) increased loss of infected cells.</p>
<p>One important finding was that to obtain clearance of HBV, as observed in patients 1 to 6 and a majority of acutely infected adults, one needs high levels of antibody, higher than usually found in clinical observation. An alternative hypothesis for the effect of antibody is that they help clear the infection, once cellular immunity controls the initial burst of replication. The CD8-antibody model shows that cytotoxic effects lead to the initial viral control, and antibodies prevent re-infection. Previously, we had shown that a refractory/immune state of target cells could preserve the integrity of the liver while preventing re-infection <xref ref-type="bibr" rid="pcbi.1003730-Ciupe1">[9]</xref>. Here we argue that antibodies could have a similar effect, with dynamics compatible with the observed levels and timing of antibodies in patients. Which of these effects is dominant, or if potentially both contribute to control of infection, needs further experimental studies.</p>
<p>One limitation of model (30) is that, for patients 2 to 7, killing of infected hepatocytes by CD8 T cells leads to more than <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e455" xlink:type="simple"/></inline-formula> liver loss. Therefore non-cytotoxic CD8 T cells effects leading to infected cells being cured and refractory to reinfection are needed to preserve liver integrity.</p>
<p>In summary, we have developed a set of models of hepatitis B infection that give insight into the opposing roles of antibody and subviral particles in the resolution of acute HBV infection. In particular, we showed that even when the virus produces a large number of subviral particles, as a decoy against antibody protection, viral clearance can still be achieved when pre-existing immunity induced through vaccination or cross immunity leads to the presence of high antibody levels early in infection. However, in individuals with low initial antibody levels, as in most unvaccinated individuals and in individuals without prior exposure to HBV, antibodies could have more of a mop up function, clearing the infection and preventing viral resurgence after a cellular immune response controls the initial infection.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pcbi.1003730.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s001" position="float" xlink:type="simple"><label>Code S1</label><caption>
<p>Sample of code used to fit model (7) to the data.</p>
<p>(DOCX)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003730.s002" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s002" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p>Stable steady state solutions for free virus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e456" xlink:type="simple"/></inline-formula>, as given by model (7), as a function of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e457" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e458" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e459" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e460" xlink:type="simple"/></inline-formula>. The other parameters are as <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003730.s003" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s003" position="float" xlink:type="simple"><label>Figure S2</label><caption>
<p>Stable steady state solutions for free virus, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e461" xlink:type="simple"/></inline-formula>, as given by model (7), as a function of <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e462" xlink:type="simple"/></inline-formula> and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e463" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e464" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e465" xlink:type="simple"/></inline-formula>. The other parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003730.s004" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s004" position="float" xlink:type="simple"><label>Figure S3</label><caption>
<p>The relative sensitive curves <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e466" xlink:type="simple"/></inline-formula> for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e467" xlink:type="simple"/></inline-formula> (red lines) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e468" xlink:type="simple"/></inline-formula> (blue lines) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e469" xlink:type="simple"/></inline-formula> (left panel), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e470" xlink:type="simple"/></inline-formula> (middle panel), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e471" xlink:type="simple"/></inline-formula> (right panel). The parameters are as in <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003730.s005" mimetype="application/postscript" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s005" position="float" xlink:type="simple"><label>Figure S4</label><caption>
<p>Free virus dynamics as given by model (7) for <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e472" xlink:type="simple"/></inline-formula> (solid line), <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e473" xlink:type="simple"/></inline-formula> (dashed line) and <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e474" xlink:type="simple"/></inline-formula> (dotted line). <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e475" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e476" xlink:type="simple"/></inline-formula>, <inline-formula><inline-graphic xlink:href="info:doi/10.1371/journal.pcbi.1003730.e477" xlink:type="simple"/></inline-formula>, and the other parameters are as <xref ref-type="table" rid="pcbi-1003730-t001">Tables 1</xref> and <xref ref-type="table" rid="pcbi-1003730-t002">2</xref> (median values).</p>
<p>(EPS)</p>
</caption></supplementary-material><supplementary-material id="pcbi.1003730.s006" mimetype="application/pdf" xlink:href="info:doi/10.1371/journal.pcbi.1003730.s006" position="float" xlink:type="simple"><label>Text S1</label><caption>
<p>Supplementary information.</p>
<p>(PDF)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pcbi.1003730-Hollinger1"><label>1</label>
<mixed-citation publication-type="other" xlink:type="simple">Hollinger F, Liang T (2001) Fields Virology, Philadelphia: Lippincott Williams &amp; Wilkins. 4th edition, pp. 2971–3036.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Rehermann1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rehermann</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Nascimbeni</surname><given-names>M</given-names></name> (<year>2005</year>) <article-title>Immunology of hepatitis B virus and hepatitis C virus infection</article-title>. <source>Nat Rev Immunol</source> <volume>5</volume>: <fpage>215</fpage>–<lpage>229</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Waters1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Waters</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pignatelli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Galpin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ishihara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>H</given-names></name> (<year>1986</year>) <article-title>Virus-neutralizing antibodies to hepatitis B virus: The nature of an immunogenic epitope to the S gene peptide</article-title>. <source>J Gen Virol</source> <volume>67</volume>: <fpage>2467</fpage>–<lpage>2473</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ferrari1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferrari</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Penna</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bertoletti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Valli</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Antoni</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1990</year>) <article-title>Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection</article-title>. <source>J Immunol</source> <volume>145</volume>: <fpage>3442</fpage>–<lpage>3449</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Guidotti1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guidotti</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hobbs</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Matzke</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Schreiber</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes</article-title>. <source>Immunity</source> <volume>4</volume>: <fpage>25</fpage>–<lpage>36</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-McClary1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McClary</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Koch</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chisari</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Guidotti</surname><given-names>L</given-names></name> (<year>2000</year>) <article-title>Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines</article-title>. <source>J Virol</source> <volume>74</volume>: <fpage>2255</fpage>–<lpage>2264</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Wieland1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wieland</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eustaquio</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Whitten-Bauer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Boyd</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chisari</surname><given-names>F</given-names></name> (<year>2005</year>) <article-title>Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>102</volume>: <fpage>9913</fpage>–<lpage>9917</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Wieland2"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wieland</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Guidotti</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chisari</surname><given-names>F</given-names></name> (<year>2000</year>) <article-title>Intrahepatic induction of Alpha/Beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice</article-title>. <source>J Virol</source> <volume>74</volume>: <fpage>4165</fpage>–<lpage>4173</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ciupe1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ciupe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dusheiko</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>The role of cells refractory to productive infection in acute hepatitis B viral dynamics</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>104</volume>: <fpage>5050</fpage>–<lpage>5055</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Guo1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Guo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Aldrich</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Saputelli</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections</article-title>. <source>J Virol</source> <volume>74</volume>: <fpage>1495</fpage>–<lpage>1505</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Chisari1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chisari</surname><given-names>F</given-names></name> (<year>2000</year>) <article-title>Viruses, immunity, and cancer: lessons from hepatitis B</article-title>. <source>Am J Pathol</source> <volume>156</volume>: <fpage>1117</fpage>–<lpage>1132</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Bertoletti1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bertoletti</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ferrari</surname><given-names>C</given-names></name> (<year>2003</year>) <article-title>Kinetics of the immune response during HBV and HCV infection</article-title>. <source>Hepatology</source> <volume>38</volume>: <fpage>4</fpage>–<lpage>13</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Lai1"><label>13</label>
<mixed-citation publication-type="book" xlink:type="simple">Lai C, Locarnini S (2002) Hepatitis B virus. London, UK: International Medical Press.</mixed-citation>
</ref>
<ref id="pcbi.1003730-AnhTuan1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Anh-Tuan</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Novk</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Holln</surname><given-names>S</given-names></name> (<year>1980</year>) <article-title>Hepatitis B surface antigen circulating immune complexes (HBsAg-CICs) in patients with bleeding disorders</article-title>. <source>J Immunol Meth</source> <volume>35</volume>: <fpage>307</fpage>–<lpage>318</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Brown1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Brown</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Steward</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Viola</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Murraylyon</surname><given-names>I</given-names></name> (<year>1983</year>) <article-title>Chronic liver disease: the detection and characterization of circulating immune complexes</article-title>. <source>Immunology</source> <volume>49</volume>: <fpage>673</fpage>–<lpage>683</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Glebe1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Glebe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lorenz</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Gerlich</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Butler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tochkov</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>1579</fpage>–<lpage>1591</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Rath1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rath</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Devey</surname><given-names>M</given-names></name> (<year>1988</year>) <article-title>IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections</article-title>. <source>Clin Exp Immunol</source> <volume>72</volume>: <fpage>164</fpage>–<lpage>167</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Prange1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Prange</surname><given-names>R</given-names></name> (<year>2012</year>) <article-title>Host factors involved in hepatitis B virus maturation, assembly, and egress</article-title>. <source>Med Microbiol Immunol</source> <volume>201</volume>: <fpage>449</fpage>–<lpage>461</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ganem1"><label>19</label>
<mixed-citation publication-type="book" xlink:type="simple">Ganem D, Schneider R (2001) Hepadnaviridae: The viruses and their replication. Philadelphia: Lippincot Williams &amp; Wilkins, 4th edition, 2924 pp.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Glebe2"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Glebe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Urban</surname><given-names>S</given-names></name> (<year>2007</year>) <article-title>Viral and cellular determinants involved in hepadnaviral entry</article-title>. <source>World J Gastroenterol</source> <volume>13</volume>: <fpage>22</fpage>–<lpage>38</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ganem2"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ganem</surname><given-names>D</given-names></name> (<year>1991</year>) <article-title>Assembly of hepadnaviral virions and subviral particles</article-title>. <source>Curr Top Microbiol Immunol</source> <volume>168</volume>: <fpage>61</fpage>–<lpage>83</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Gilbert1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gilbert</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Beales</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Blond</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Simon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Hepatitis B small surface antigen particles are octahedral</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>102</volume>: <fpage>14783</fpage>–<lpage>14788</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Patient1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Patient</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hourioux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Roingeard</surname><given-names>P</given-names></name> (<year>2009</year>) <article-title>Morphogenesis of hepatitis B virus and its subviral envelope particles</article-title>. <source>Cell Microbiol</source> <volume>11</volume>: <fpage>1561</fpage>–<lpage>1570</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Garcia1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garcia</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sureau</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>Y</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion</article-title>. <source>J Virol</source> <volume>83</volume>: <fpage>11152</fpage>–<lpage>11165</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Nowak1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nowak</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Boehme</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Viral dynamics in hepatitis B infection</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>93</volume>: <fpage>4398</fpage>–<lpage>4402</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Nowak2"><label>26</label>
<mixed-citation publication-type="book" xlink:type="simple">Nowak M, May R (2000) Virus Dynamics. Oxford: Oxford University Press.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Perelson1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name> (<year>2002</year>) <article-title>Modelling viral and immune system dynamics</article-title>. <source>Nature Rev Immunol</source> <volume>2</volume>: <fpage>28</fpage>–<lpage>36</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Perelson2"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leonard</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>D</given-names></name> (<year>1996</year>) <article-title>HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time</article-title>. <source>Science</source> <volume>271</volume>: <fpage>1582</fpage>–<lpage>1586</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Stafford1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stafford</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Corey</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cap</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Daar</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ho</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Modeling plasma virus concentration during primary HIV infection</article-title>. <source>J Theor Biol</source> <volume>203</volume>: <fpage>285</fpage>–<lpage>301</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Lewin1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lewin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Walters</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lau</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Bowden</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Analysis of hepatitis B viral load decline under potent therapy:complex decay profiles observed</article-title>. <source>Hepatology</source> <volume>34</volume>: <fpage>1012</fpage>–<lpage>1020</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Tsiang1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tsiang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rooney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Toole</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gibbs</surname><given-names>C</given-names></name> (<year>1999</year>) <article-title>Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy</article-title>. <source>Hepatology</source> <volume>29</volume>: <fpage>1863</fpage>–<lpage>1869</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Lambotte1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lambotte</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Saliez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Triest</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tagliaferri</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Barker</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>1997</year>) <article-title>Control of rate and extent of the proliferative response after partial hepatectomy</article-title>. <source>Am J Physiol</source> <volume>273</volume>: <fpage>G905</fpage>–<lpage>G912</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Michalopoulos1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Michalopoulos</surname><given-names>G</given-names></name>, <name name-style="western"><surname>DeFrances</surname><given-names>M</given-names></name> (<year>1997</year>) <article-title>Liver regeneration</article-title>. <source>Science</source> <volume>276</volume>: <fpage>60</fpage>–<lpage>66</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ciupe2"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ciupe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>Modeling the mechanisms of acute hepatitis B virus infection</article-title>. <source>J Theor Biol</source> <volume>247</volume>: <fpage>23</fpage>–<lpage>35</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Bonhoeffer1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bonhoeffer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>May</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nowak</surname><given-names>M</given-names></name> (<year>1997</year>) <article-title>Virus dynamics and drug therapy</article-title>. <source>Proc Nat Acad Sci USA</source> <volume>94</volume>: <fpage>6971</fpage>–<lpage>6976</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Ribeiro1"><label>36</label>
<mixed-citation publication-type="book" xlink:type="simple">Ribeiro R, Dixit N, Perelson A (2006) Modelling the in vivo growth rate of HIV: implications for vaccination. Multidisciplinary approaches to theory in medicine. Amsterdam, Netherlands: Elsevier, 231–246 pp.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Nowak3"><label>37</label>
<mixed-citation publication-type="book" xlink:type="simple">Nowak M, May R (2001) Virus dynamics: Mathematical principles of immunology and virology. Oxford University Press.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Murray1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wieland</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Purcell</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Chisari</surname><given-names>F</given-names></name> (<year>2005</year>) <article-title>Dynamics of hepatitis B virus clearance in chimpanzees</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>102</volume>: <fpage>17780</fpage>–<lpage>17785</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Sprengers1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sprengers</surname><given-names>D</given-names></name>, <name name-style="western"><surname>van der Molen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kusters</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Man</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Niesters</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans</article-title>. <source>J Hepatol</source> <volume>45</volume>: <fpage>182</fpage>–<lpage>189</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Yousfi1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yousfi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hattaf</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tridane</surname><given-names>A</given-names></name> (<year>2011</year>) <article-title>Modeling the adaptive immune response in HBV infection</article-title>. <source>J Math Biol</source> <volume>63</volume>: <fpage>933</fpage>–<lpage>957</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Kandathil1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kandathil</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Graw</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Quinn</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Torbenson</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver</article-title>. <source>Gastroenterol</source> <volume>145</volume>: <fpage>1404</fpage>–<lpage>1413</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Dibrov1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dibrov</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Livshits</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Volkenstein</surname><given-names>M</given-names></name> (<year>1977</year>) <article-title>Mathematical model of immune processes</article-title>. <source>J Theor Biol</source> <volume>65</volume>: <fpage>609</fpage>–<lpage>631</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Oprea1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Oprea</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name> (<year>1996</year>) <article-title>Exploring the mechanisms of primary antibody responses to T cell-dependent antigens</article-title>. <source>J Theor Biol</source> <volume>181</volume>: <fpage>215</fpage>–<lpage>236</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Lodish1"><label>44</label>
<mixed-citation publication-type="book" xlink:type="simple">Lodish H, Berk A, Matsudaira P, Kaiser C, Krieger M, <etal>et al</etal>.. (2004) Molecular Cell Biology. San Francisco, CA: WH Freeman &amp; Co, 5th edition.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Sherlock1"><label>45</label>
<mixed-citation publication-type="book" xlink:type="simple">Sherlock S, Dooley J (2002) Diseases of the Liver and Biliary System. Oxford: Blackwell Science, 11 edition, 1–9 pp.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Dahari1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dahari</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Cotler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Layden</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Perelson</surname><given-names>A</given-names></name> (<year>2009</year>) <article-title>Hepatitis B virus clearance rate estimates</article-title>. <source>Hepatology</source> <volume>49</volume>: <fpage>1779</fpage>–<lpage>1780</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Dati1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dati</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Schumann</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Aguzzi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Baudner</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470)</article-title>. <source>Eur J Clin Chem Clin Biochem</source> <volume>34</volume>: <fpage>517</fpage>–<lpage>520</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-GonzalezQuintela1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gonzalez-Quintela</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alende</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gude</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Campos</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rey</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities</article-title>. <source>Clin Exp Immunol</source> <volume>151</volume>: <fpage>42</fpage>–<lpage>50</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Morell1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morell</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Terry</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Waldmann</surname><given-names>T</given-names></name> (<year>1970</year>) <article-title>Metabolic properties of IgG subclasses in man</article-title>. <source>J Clin Invest</source> <volume>49</volume>: <fpage>673</fpage>–<lpage>680</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Rossi1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rossi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Azzari</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Resti</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Appendino</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pezzati</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>1988</year>) <article-title>Selectivity in IgG subclass response to hepatitis B vaccine in infants born to HBsAg-positive mothers</article-title>. <source>Clin Exp Immunol</source> <volume>72</volume>: <fpage>196</fpage>–<lpage>200</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Rath2"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rath</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Devey</surname><given-names>M</given-names></name> (<year>1988</year>) <article-title>IgG subclass composition of antibodies to HBsAg in circulating immune complexes from patients with hepatitis B virus infections</article-title>. <source>Clin Exp Immunol</source> <volume>72</volume>: <fpage>164</fpage>–<lpage>167</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Schwesinger1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Schwesinger</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ros</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Strunz</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Anselmetti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Guntherodt</surname><given-names>HJ</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>97</volume>: <fpage>9972</fpage>–<lpage>9977</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Gopalakrishnan1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gopalakrishnan</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Karush</surname><given-names>F</given-names></name> (<year>1975</year>) <article-title>Antibody affinity. VIII. measurement of affinity of anti-lactose antibody by fluorescence quenching with a DNP-containing ligand</article-title>. <source>J Immunol</source> <volume>114</volume>: <fpage>1359</fpage>–<lpage>1362</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Roost1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Roost</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bachmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Haag</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kalinke</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Pliska</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>1995</year>) <article-title>Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>92</volume>: <fpage>1257</fpage>–<lpage>1261</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Igarashi1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Igarashi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Azadegan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Haigwood</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Dimitrov</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma</article-title>. <source>Nat Med</source> <volume>5</volume>: <fpage>211</fpage>–<lpage>216</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Webster1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Webster</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hallett</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Whalley</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Meltzer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Balogun</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>Molecular epidemiology of a large outbreak of hepatitis B linked to autohaemotherapy</article-title>. <source>Lancet</source> <volume>356</volume>: <fpage>379</fpage>–<lpage>384</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Whalley1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Whalley</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Webster</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Emery</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Kinetics of acute hepatitis B virus infection in humans</article-title>. <source>J Exp Med</source> <volume>193</volume>: <fpage>847</fpage>–<lpage>853</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Klasse1"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Klasse</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sattentau</surname><given-names>Q</given-names></name> (<year>2002</year>) <article-title>Occupancy and mechanism in antibody- mediated neutralization of animal viruses</article-title>. <source>J Gen Virol</source> <volume>83</volume>: <fpage>2091</fpage>–<lpage>2108</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Yang1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>SKS</given-names></name>, <name name-style="western"><surname>Sodroski</surname><given-names>J</given-names></name> (<year>2005</year>) <article-title>Stoichiometry of antibody neutralization of human immunodeficiency virus type 1</article-title>. <source>J Virol</source> <volume>79</volume>: <fpage>3500</fpage>–<lpage>3508</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Magnus1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Magnus</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Regoes</surname><given-names>R</given-names></name> (<year>2011</year>) <article-title>Restricted occupancy models for neutralization of HIV virions and populations</article-title>. <source>J Theor Biol</source> <volume>283</volume>: <fpage>192</fpage>–<lpage>202</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Magnus2"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Magnus</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Virus neutralisation: New insights from kinetic neutralisation curves</article-title>. <source>PLoS Comput Biol</source> <volume>9</volume>: <fpage>e1002900</fpage> <comment>doi:<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pcbi.1002900" xlink:type="simple">10.1371/journal.pcbi.1002900</ext-link></comment></mixed-citation>
</ref>
<ref id="pcbi.1003730-IgG1"><label>62</label>
<mixed-citation publication-type="other" xlink:type="simple">IgG Human ELISA Kit ab100547 <ext-link ext-link-type="uri" xlink:href="http://www.abcam.com/IgG-Human-ELISA-Kit-ab100547.html" xlink:type="simple">http://www.abcam.com/IgG-Human-ELISA-Kit-ab100547.html</ext-link>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Bortz1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bortz</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>P</given-names></name> (<year>2004</year>) <article-title>Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics</article-title>. <source>Bull Math Biol</source> <volume>66</volume>: <fpage>1009</fpage>–<lpage>1026</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Tabei1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tabei</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Weigert</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dinner</surname><given-names>A</given-names></name> (<year>2012</year>) <article-title>Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV</article-title>. <source>Vaccine</source> <volume>30</volume>: <fpage>607</fpage>–<lpage>613</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Tomaras1"><label>65</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tomaras</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Yates</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fouda</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin IgM and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia</article-title>. <source>J Virol</source> <volume>82</volume>: <fpage>12449</fpage>–<lpage>12463</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Hadler1"><label>66</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hadler</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Margolis</surname><given-names>H</given-names></name> (<year>1992</year>) <article-title>Hepatitis B immunization: vaccine types, efficacy, and indications for immunization</article-title>. <source>Curr Clin Top Infect Dis</source> <volume>12</volume>: <fpage>282</fpage>–<lpage>308</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-McMahon1"><label>67</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McMahon</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bruden</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Petersen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bulkow</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Parkinson</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up</article-title>. <source>Ann Intern Med</source> <volume>142</volume>: <fpage>333</fpage>–<lpage>341</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-McMahon2"><label>68</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McMahon</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dentinger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bruden</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Zanis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Peters</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Antibody levels and protection after hepatitis B vaccine: Results of a 22-year follow-up study and response to a booster dose</article-title>. <source>J Inf Dis</source> <volume>200</volume>: <fpage>1390</fpage>–<lpage>1396</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Cejka1"><label>69</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cejka</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mood</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>C</given-names></name> (<year>1974</year>) <article-title>Immunoglobulin concentrations in sera of normal children: quantitation against an international reference preparation</article-title>. <source>Clin Chem</source> <volume>20</volume>: <fpage>656</fpage>–<lpage>659</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Parkin1"><label>70</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Parkin</surname><given-names>D</given-names></name> (<year>2006</year>) <article-title>The global health burden of infection-associated cancers in the year 2002</article-title>. <source>Int J Cancer</source> <volume>118</volume>: <fpage>3030</fpage>–<lpage>3044</lpage>.</mixed-citation>
</ref>
<ref id="pcbi.1003730-Read1"><label>71</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Read</surname><given-names>S</given-names></name> (<year>2001</year>) <article-title>Recovery efficiencies of nucleic acid extraction kits as measured by quantitative LightCycler TM PCR</article-title>. <source>Mol Path</source> <volume>54</volume>: <fpage>86</fpage>–<lpage>90</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>